Department of Dermatology, Zurich University Hospital, Schlieren, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland; HypoPet AG, Zurich, Switzerland.
Department of Dermatology, Zurich University Hospital, Schlieren, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland; HypoPet AG, Zurich, Switzerland.
J Allergy Clin Immunol. 2019 Jul;144(1):193-203. doi: 10.1016/j.jaci.2019.01.050. Epub 2019 May 2.
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms.
We developed a new strategy to treat Fel d 1-induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1.
A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin-derived universal T-cell epitope tt830-843 (CuMV) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMV vaccine alone or in combination with an adjuvant.
The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti-Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed.
Vaccination of cats with Fel-CuMV induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters.
人类的猫过敏通常是由主要过敏原猫过敏原 1（Fel d 1）引起的，约 10%的西方人口存在这种情况。目前，尚无针对猫过敏的有效且安全的治疗方法。过敏患者通常试图避免接触猫或治疗其过敏症状。
我们开发了一种新策略，通过免疫猫使其自身产生主要过敏原 Fel d 1，从而治疗人类 Fel d 1 诱导的过敏。
使用由重组 Fel d 1 和黄瓜花叶病毒（CuMV）衍生的病毒样颗粒组成的缀合疫苗，该颗粒包含破伤风毒素衍生的通用 T 细胞表位 tt830-843（CuMV），对猫进行免疫。单独或联合佐剂进行了 Fel-CuMV 疫苗的首次耐受性和免疫原性研究，包括加强注射。
该疫苗具有良好的耐受性，没有明显的毒性作用。所有猫均诱导出强烈且持续的特异性 IgG 抗体反应。诱导的抗 Fel d 1 抗体具有高亲和力，并表现出在体外和体内均具有很强的中和能力。观察到内源性过敏原水平降低和泪液样本的变应原性降低。
用 Fel-CuMV 给猫接种疫苗可诱导中和抗体，并可能导致过敏猫主人的症状减轻。人和动物都可以从这种治疗中受益，因为过敏的猫主人会降低患哮喘等慢性疾病的风险，并且对他们的猫更耐受，因此猫可以留在家庭中，而无需被送进动物收容所。
